A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia

Brief Summary

Official Title: “A Retrospective, Non-interventional Study to Evaluate the Use of Seroquel XR and Seroquel IR in the Clinical Practice of Outpatients With Schizophrenia”

The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia. This will be done by a retrospective review of medical records to evaluate patients treated with Seroquel XR or Seroquel IR as primary antipsychotic treatment.

  • Study Type: Observational
  • Study Design: Observational Model: Case Control, Time Perspective: Retrospective
  • Study Primary Completion Date: February 2011

Arms, Groups and Cohorts in this Clinical Trial

  • 300 patients
    • Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January – March 2010

Outcome Measures for this Clinical Trial

Primary Measures

  • How Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia
    • Time Frame: Month 1
      Safety Issue?: No
  • How Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia
    • Time Frame: Month 2
      Safety Issue?: No
  • How Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia
    • Time Frame: Month 3
      Safety Issue?: No

Secondary Measures

  • Co-morbidities of patients with schizophrenia receiving Seroquel XR and IR
    • Time Frame: Month 1
      Safety Issue?: No
  • Co-morbidities of patients with schizophrenia receiving Seroquel XR and IR
    • Time Frame: Month 2
      Safety Issue?: No
  • Co-morbidities of patients with schizophrenia receiving Seroquel XR and IR
    • Time Frame: Month 3
      Safety Issue?: No
  • Whether Seroquel XR and Seroquel IR are used to treat different types of outpatients with schizophrenia by evaluation of patient characteristics
    • Time Frame: Month 1
      Safety Issue?: No
  • Whether Seroquel XR and Seroquel IR are used to treat different types of outpatients with schizophrenia by evaluation of patient characteristics
    • Time Frame: Month 2
      Safety Issue?: No
  • Whether Seroquel XR and Seroquel IR are used to treat different types of outpatients with schizophrenia by evaluation of patient characteristics
    • Time Frame: Month 3
      Safety Issue?: No
  • The treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR
    • Time Frame: Month 1
      Safety Issue?: No
  • The treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR
    • Time Frame: Month 2
      Safety Issue?: No
  • The treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR
    • Time Frame: Month 3
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Adults with a diagnosis of schizophrenia from a district psychiatric clinic in Denmark
  • Patients who have received at least one dose of Seroquel XR or Seroquel IR during January – March 2010

Exclusion Criteria

  • Patients already participating in a clinical study during the study-period.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Eva Dencker Vansvik, Marketing Company Medical Director (MC MD), AstraZeneca
  • Overall Official(s)
    • Eva Dencker Vansvik, Study Director, AstraZeneca Nordic-Södertälje, Sweden
    • Charlotte Emborg, Principal Investigator, Skovager 2, Risskov, Denmark

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01212575